ストックスクリーナーアプリを入手
17.94
15.44%
2.40
アフターアワーズ：
17.85
-0.09
-0.50%
前日終値:
$15.54
開ける：
$15.93
24時間の取引高:
5.26M
Relative Volume:
2.05
時価総額：
$13.91B
収益：
$220.00K
当期純損益:
$-1.08B
株価収益率:
-12.42
EPS:
-1.4448
ネットキャッシュフロー:
$-326.53M
1週間 パフォーマンス:
+15.00%
1か月 パフォーマンス:
+14.41%
6か月 パフォーマンス:
-11.45%
1年 パフォーマンス:
-11.36%
1日の値動き範囲:
$15.84
$17.98
1週間の範囲:
$15.25
$17.98
52週間の値動き範囲:
$13.83
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Compare SMMT vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
17.94 | 12.05B | 220.00K | -1.08B | -326.53M | -1.4448 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | ダウングレード | Jefferies | Buy → Hold |
| 2025-12-17 | アップグレード | Barclays | Underweight → Equal Weight |
| 2025-11-18 | 開始されました | Wolfe Research | Peer Perform |
| 2025-09-17 | 開始されました | Barclays | Underweight |
| 2025-09-04 | 開始されました | Guggenheim | Buy |
| 2025-08-19 | 開始されました | Piper Sandler | Neutral |
| 2025-07-01 | 開始されました | UBS | Buy |
| 2025-06-11 | 開始されました | Leerink Partners | Underperform |
| 2025-03-26 | アップグレード | Citigroup | Neutral → Buy |
| 2025-03-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-03-12 | 開始されました | Evercore ISI | Outperform |
| 2025-02-28 | 開始されました | Goldman | Buy |
| 2025-01-08 | 開始されました | Truist | Buy |
| 2024-12-11 | 開始されました | Wells Fargo | Overweight |
| 2024-12-06 | 開始されました | Jefferies | Buy |
| 2024-11-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-09-27 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-08-12 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-07 | 開始されました | Citigroup | Buy |
| 2024-03-26 | 開始されました | Stifel | Buy |
| 2018-06-28 | ダウングレード | Janney | Buy → Neutral |
| 2018-05-02 | 開始されました | Janney | Buy |
| 2018-04-12 | 繰り返されました | Needham | Buy |
| 2018-02-13 | 開始されました | BTIG Research | Buy |
| 2018-01-04 | 開始されました | SunTrust | Buy |
| 2017-12-01 | 再開されました | H.C. Wainwright | Buy |
| 2016-11-16 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2016-10-05 | 繰り返されました | Needham | Buy |
| 2016-09-16 | 開始されました | H.C. Wainwright | Buy |
| 2015-03-30 | 開始されました | Needham | Buy |
| 2015-03-30 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Summit Therapeutics Inc (SMMT) 最新ニュース
Summit Therapeutics (SMMT) Climbs 15.4% Ahead of Pipeline Q2 Updates - Yahoo Finance UK
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now - Yahoo Finance
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now - The Motley Fool
U.S. Markets Rose Wednesday; Summit Therapeutics Topped Leaders - Barron's
Summit Therapeutics Enters Strong Growth Phase Amid Partnerships and Trials - StocksToTrade
Summit Therapeutics (NASDAQ:SMMT) Trading 12.1% HigherHere's What Happened - MarketBeat
Summit Therapeutics Inc. (SMMT) focused on non-small cell lung cancer trial of Ivonescimab - MSN
Summit Therapeutics (SMMT) Stock Price Prediction for 2026, 2030-2040 - Traders Union
347,241 Shares in Summit Therapeutics PLC $SMMT Acquired by Tudor Investment Corp ET AL - MarketBeat
Responsive Playbooks and the SMMT Inflection - Stock Traders Daily
Trade Recap: Does Summit Therapeutics Inc have a sustainable dividend2026 Investor Takeaways & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Analysts Are Bullish on Top Healthcare Stocks: Scholar Rock Holding (SRRK), Summit Therapeutics (SMMT) - The Globe and Mail
SMMT PE Ratio & Valuation, Is SMMT Overvalued - Intellectia AI
Summit Therapeutics Inc.Common Stock (NQ: SMMT - FinancialContent
Jefferies downgrades Summit Therapeutics (SMMT) - MSN
Should Jefferies’ Downgrade and Ivonesimab Focus Shape Summit Therapeutics’ (SMMT) Risk‑Reward Profile? - simplywall.st
SMMT Downgraded by Jefferies, Price Target Slashed by 64% | SMMT Stock News - GuruFocus
Summit Therapeutics (NASDAQ:SMMT) Rating Lowered to "Hold" at Jefferies Financial Group - MarketBeat
Summit Therapeutics downgraded to Hold from Buy at Jefferies - TipRanks
SMMT SEC FilingsSummit Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Summit Therapeutics (NASDAQ:SMMT) Trading 6.5% HigherTime to Buy? - MarketBeat
How correlated is Summit Therapeutics Inc to the S P5002026 Chart Watch & Advanced Technical Signal Analysis - baoquankhu1.vn
WINTON GROUP Ltd Makes New Investment in Summit Therapeutics PLC $SMMT - MarketBeat
Understanding the Setup: (SMMT) and Scalable Risk - Stock Traders Daily
Summit Therapeutics at The Citizens Life Sciences Conference: Strategic Insights on Ivonescimab - Investing.com Nigeria
Earnings Report: Is Summit Therapeutics Inc impacted by rising ratesQuarterly Portfolio Review & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Earnings Recap: How correlated is Summit Therapeutics Inc to the S P5002026 Outlook & Reliable Entry Point Alerts - baoquankhu1.vn
Summit Therapeutics’ Earnings Call Highlights OS Hurdles - The Globe and Mail
Summit Therapeutics (NASDAQ:SMMT) Upgraded by Zacks Research to Hold Rating - MarketBeat
Summit Therapeutics (SMMT) ends 2025 with strong cash reserves and increased clinical investment - MSN
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Aug Outlook: Can Summit Therapeutics Inc stock outperform in a bear marketDollar Strength & Risk Managed Investment Entry Signals - baoquankhu1.vn
Why Summit Therapeutics (SMMT) Is Down 6.3% After Wider 2025 Loss and ESOP Shelf Filing - simplywall.st
Is Summit Therapeutics (SMMT) Now Pricing In Too Much Hope After Strong Multi Year Gains - simplywall.st
Rafferty Asset Management LLC Purchases 140,323 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
Is Summit Therapeutics (SMMT) Pricing Reflect Long Term Value After Recent Share Price Swings - Yahoo Finance
Summit Therapeutics (SMMT) Ends 2025 With Strong Cash Reserves and Increased Clinical Investment - Finviz
10 Stocks With Explosive Growth Potential - Insider Monkey
Summit Therapeutics at TD Cowen Conference: Strategic Focus on Ivonesimab - Investing.com
SMMT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Summit Therapeutics Inc. (SMMT) Stock Analysis: Biotech Innovator with an 89.92% Potential Upside - DirectorsTalk Interviews
Vanguard Group Inc. Purchases 2,706,056 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics Inc. (SMMT) Focused on Non-Small Cell Lung Cancer Trial of Ivonescimab - Insider Monkey
The Technical Signals Behind (SMMT) That Institutions Follow - Stock Traders Daily
11 Best Cancer Stocks to Invest In Now - Insider Monkey
Q1 EPS Estimate for Summit Therapeutics Increased by Analyst - MarketBeat
Summit Therapeutics Inc (SMMT) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):